第四届国际更年期专家论坛决议

Q4 Medicine
{"title":"第四届国际更年期专家论坛决议","authors":"","doi":"10.18370/2309-4117.2023.69.2-6","DOIUrl":null,"url":null,"abstract":"The IV International Menopause Expert Forum took place on November 24, 2022. The expert panel included leading endocrine gynaecologists from Armenia, Azerbaijan, Georgia, Kazakhstan, Moldova, Ukraine, Uzbekistan, and Ukraine. The experts discussed interdisciplinary cooperation in the management of menopausal women, the eligibility criteria for menopausal hormone therapy (MHT) and their implementation in routine clinical practice and developed an algorithm for switching from combined oral contraceptives (COCs) to MHT. Due to the lack of awareness and access to information and services related to menopause, interdisciplinary cooperation aimed at early detection of symptoms and diagnosis of menopausal disorders for timely treatment is paramount. The Forum participants highlighted the need for a series of steps to ensure comprehensive management of menopausal women. The Expert Forum reviewed the 2022 «Eligibility criteria for menopausal hormone therapy: a position statement from a consortium of scientific societies for the use of MHT in women with medical conditions». The developed criteria for the acceptability of different MHT types for women with comorbidities is an essential step in expanding the possibilities for the use of MHT by physicians of various therapeutic areas. Moreover, the criteria help to identify populations for whom certain types of MHT are associated with risks. Importantly, the discussed eligibility criteria are not yet universally accepted. Therefore, in routine clinical practice, when deciding whether to prescribe a particular type of MHT, it is vital to take an individual approach and assess the benefit/risk balance, considering the patient’s combination of comorbidities, medical history, as well as the strengths and components of combination MHT, particularly the gestational component.Perimenopausal women may need contraception, including COCs. In such circumstances, physicians are faced with such questions as the acceptability of prescribing or continuing to use COCs for menopausal women, as well as when and how to switch from COCs to MHT. Thus, the Forum developed an algorithm for switching from COCs to MHT.","PeriodicalId":21103,"journal":{"name":"Reproductive Endocrinology","volume":"28 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Resolution of the IV International Menopause Expert Forum\",\"authors\":\"\",\"doi\":\"10.18370/2309-4117.2023.69.2-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The IV International Menopause Expert Forum took place on November 24, 2022. The expert panel included leading endocrine gynaecologists from Armenia, Azerbaijan, Georgia, Kazakhstan, Moldova, Ukraine, Uzbekistan, and Ukraine. The experts discussed interdisciplinary cooperation in the management of menopausal women, the eligibility criteria for menopausal hormone therapy (MHT) and their implementation in routine clinical practice and developed an algorithm for switching from combined oral contraceptives (COCs) to MHT. Due to the lack of awareness and access to information and services related to menopause, interdisciplinary cooperation aimed at early detection of symptoms and diagnosis of menopausal disorders for timely treatment is paramount. The Forum participants highlighted the need for a series of steps to ensure comprehensive management of menopausal women. The Expert Forum reviewed the 2022 «Eligibility criteria for menopausal hormone therapy: a position statement from a consortium of scientific societies for the use of MHT in women with medical conditions». The developed criteria for the acceptability of different MHT types for women with comorbidities is an essential step in expanding the possibilities for the use of MHT by physicians of various therapeutic areas. Moreover, the criteria help to identify populations for whom certain types of MHT are associated with risks. Importantly, the discussed eligibility criteria are not yet universally accepted. Therefore, in routine clinical practice, when deciding whether to prescribe a particular type of MHT, it is vital to take an individual approach and assess the benefit/risk balance, considering the patient’s combination of comorbidities, medical history, as well as the strengths and components of combination MHT, particularly the gestational component.Perimenopausal women may need contraception, including COCs. In such circumstances, physicians are faced with such questions as the acceptability of prescribing or continuing to use COCs for menopausal women, as well as when and how to switch from COCs to MHT. Thus, the Forum developed an algorithm for switching from COCs to MHT.\",\"PeriodicalId\":21103,\"journal\":{\"name\":\"Reproductive Endocrinology\",\"volume\":\"28 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-09-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Reproductive Endocrinology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.18370/2309-4117.2023.69.2-6\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reproductive Endocrinology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18370/2309-4117.2023.69.2-6","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

第四届国际更年期专家论坛于 2022 年 11 月 24 日举行。专家小组成员包括来自亚美尼亚、阿塞拜疆、格鲁吉亚、哈萨克斯坦、摩尔多瓦、乌克兰、乌兹别克斯坦和乌克兰的顶尖妇科内分泌专家。专家们讨论了更年期妇女管理中的跨学科合作、更年期激素疗法(MHT)的资格标准及其在常规临床实践中的实施,并制定了从复方口服避孕药(COCs)转向更年期激素疗法的算法。由于缺乏对更年期相关信息和服务的了解和获取途径,旨在早期发现更年期症状和诊断更年期失调以进行及时治疗的跨学科合作至关重要。论坛与会者强调有必要采取一系列措施,确保对更年期妇女进行全面管理。专家论坛审查了 2022 年 "更年期激素疗法的资格标准:科学协会联合会关于在有病症的妇女中使用更年期激素疗法的立场声明"。为有合并症的妇女制定的不同类型更年期激素疗法的可接受性标准是扩大不同治疗领域的医生使用更年期激素疗法的可能性的重要一步。此外,这些标准还有助于确定某些类型的人工晶体植入术对哪些人群具有风险。重要的是,所讨论的资格标准尚未得到普遍接受。因此,在常规临床实践中,在决定是否开具特定类型的 MHT 时,必须采取因人而异的方法,评估收益/风险的平衡,考虑患者的合并症、病史以及联合 MHT 的优势和组成部分,尤其是妊娠组成部分。在这种情况下,医生面临着为绝经期妇女开具或继续使用 COCs 的可接受性,以及何时和如何从 COCs 转为 MHT 等问题。因此,论坛制定了一个从 COCs 转为 MHT 的算法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Resolution of the IV International Menopause Expert Forum
The IV International Menopause Expert Forum took place on November 24, 2022. The expert panel included leading endocrine gynaecologists from Armenia, Azerbaijan, Georgia, Kazakhstan, Moldova, Ukraine, Uzbekistan, and Ukraine. The experts discussed interdisciplinary cooperation in the management of menopausal women, the eligibility criteria for menopausal hormone therapy (MHT) and their implementation in routine clinical practice and developed an algorithm for switching from combined oral contraceptives (COCs) to MHT. Due to the lack of awareness and access to information and services related to menopause, interdisciplinary cooperation aimed at early detection of symptoms and diagnosis of menopausal disorders for timely treatment is paramount. The Forum participants highlighted the need for a series of steps to ensure comprehensive management of menopausal women. The Expert Forum reviewed the 2022 «Eligibility criteria for menopausal hormone therapy: a position statement from a consortium of scientific societies for the use of MHT in women with medical conditions». The developed criteria for the acceptability of different MHT types for women with comorbidities is an essential step in expanding the possibilities for the use of MHT by physicians of various therapeutic areas. Moreover, the criteria help to identify populations for whom certain types of MHT are associated with risks. Importantly, the discussed eligibility criteria are not yet universally accepted. Therefore, in routine clinical practice, when deciding whether to prescribe a particular type of MHT, it is vital to take an individual approach and assess the benefit/risk balance, considering the patient’s combination of comorbidities, medical history, as well as the strengths and components of combination MHT, particularly the gestational component.Perimenopausal women may need contraception, including COCs. In such circumstances, physicians are faced with such questions as the acceptability of prescribing or continuing to use COCs for menopausal women, as well as when and how to switch from COCs to MHT. Thus, the Forum developed an algorithm for switching from COCs to MHT.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Reproductive Endocrinology
Reproductive Endocrinology Medicine-Obstetrics and Gynecology
CiteScore
0.50
自引率
0.00%
发文量
13
审稿时长
8 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信